Recommended reading
-
Bogoch ER, Elliot-Gibson V, Beaton DE, et al.
Effective initiation of osteoporosis diagnosis and treatment for patients with a fragility fracture in an orthopaedic environment. J Bone Joint Surg Am. 2006 Jan;88(1):25–34.
-
World Health Organization.
Guidelines for preclinical evaluation and clinical trials in osteoporosis. Geneva: WHO;1998:59. Available at: http://www.who.int/iris/handle/10665/42088. Accessed September 2013.
-
Rabar S, Lau R, O'Flynn N, et al.
Risk assessment of fragility fractures: summary of NICE guidance. BMJ. 2012 Aug 8;345. doi:10.1136/bmj.e3698.
-
Kanis JA, McCloskey EV, Johansson H, et al.
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013 Jan;24(1):23–57.
-
Verbrugge FH, Gielen E, Milisen K, et al.
Who should receive calcium and vitamin D supplementation? Age Ageing. 2012 Sep;41(5):576–580.
-
Holick MF, Binkley NC, Bischoff-Ferrari HA, et al.
Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab. 2012 Apr;97(4):1153–1158.
-
Sinha A, Cheetham TD, Pearce SH.
Prevention and treatment of vitamin D deficiency. Calcif Tissue Int. 2013 Feb;92(2):207–215.
-
Brown EM, Hebert SC.
Calcium-receptor-regulated parathyroid and renal function. Bone. 1997 Apr;20(4):303–309.
-
Khairallah W, Fawaz A, Brown EM, et al.
Hypercalcemia and diabetes insipidus in a patient previously treated with lithium. Nat Clin Pract Nephrol. 2007 Jul;3(7):397–404.
-
Shoback D.
Clinical practice. Hypoparathyroidism. N Engl J Med. 2008 Jul 24;359(4):391–403.
-
Gates BJ, Sonnett TE, Duvall CA, et al.
Review of osteoporosis pharmacotherapy for geriatric patients. Am J Geriatr Pharmacother. 2009 Dec;7(6):293–323.
-
Curtis JR, Arora T, Matthews RS, et al.
Is withholding osteoporosis medication after fracture sometimes rational? A comparison of the risk for second fracture versus death. J Am Med Dir Assoc. 2010 Oct;11(8):584–591.
-
Charlson M, Szatrowski TP, Peterson J, et al.
Validation of a combined comorbidity index. J Clin Epidemiol. 1994 Nov;47(11):1245–1251.
-
Mahoney FI, Barthel DW.
Functional evaluation: the Barthel Index. Md State Med J. 1965 Feb;14:61–65.
-
Parker MJ, Palmer CR.
A new mobility score for predicting mortality after hip fracture. J Bone Joint Surg Br. 1993 Sep;75(5):797–798.
-
Kammerlander C, Gosch M, Kammerlander-Knauer U, et al.
Long-term functional outcome in geriatric hip fracture patients. Arch Orthop Trauma Surg. 2011 Oct;131(10):1435–1444.
-
Eriksen EF, Lyles KW, Colón-Emeric CS, et al.
Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res. 2009 Jul;24(7):1308–1313.
-
Queally JM, Kiernan C, Shaikh M, et al.
Initiation of osteoporosis assessment in the fracture clinic results in improved osteoporosis management: a randomised controlled trial. Osteoporos Int. 2013 Mar;24(3):1089–1094.
-
Lyles KW, Colón-Emeric CS, Magaziner JS, et al.
Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture. N Engl J Med. 2007; 357:1799–1809.
-
Boonen S, Black DM, Colón-Emeric CS, et al.
Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc. 2010 Feb;58(2):292–299.
-
Diez-Perez A, Adachi JD, Agnusdei D, et al.
Treatment failure in osteoporosis. Osteoporos Int. 2012 Dec;23(12):2769–2774.
-
Feldstein AC, Weycker D, Nichols GA, et al.
Effectiveness of bisphosphonate therapy in a community setting. Bone. 2009 Jan;44(1):153–159.
-
Falck-Ytter Y, Francis CW, Johanson NA, et al.
Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e278S–325S.